Search results
CARsgen’s CAR T MM therapy shows early signs of efficacy in Phase I trial
Clinical Trials Arena via Yahoo Finance· 2 days agoT cell therapy accounts for 55% of all adoptive cell therapy trials, according to data obtained ...
Why Is Mustang Bio (MBIO) Stock Up 347% Today?
InvestorPlace· 2 days agoThe recent news includes favorable results from the company’s Phase 1/2 clinical trial of MB-106. This is a CD20-targeted, autologous CAR T< ...
Kyverna's CAR-T relapse in lupus dents autoimmune hopes amid biotech gold rush
FierceBiotech· 2 days agoT-cell therapy (CAR-T) in lupus has led to a gold rush as cell therapy ...
FDA official: The risk of secondary cancer from CAR-T therapy is less than feared
Medical Xpress· 2 days agoThe risk of secondary cancer after CAR-T therapy, pioneered at Penn, is less than regulators feared...
EU regulator mandates label updates on CAR-T cancer therapies
Reuters· 5 days agoThe European health regulator said on Friday product information for a class of cancer therapies...
APAC leaps ahead in adoptive cell therapy space
Pharmaceutical Technology via Yahoo Finance· 2 days agoGlobalData is the parent company of Pharmaceutical Technology. Adoptive cell therapies are immunotherapies that use engineered cells to...immunotherapy,...
Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically
Digital Journal· 19 hours ago...Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated small molecules and their formulations, intended for the...on cancer, can come in various forms; including: checkpoint...
Piper Sandler keeps 'Overweight' on Allogene stock, highlights CAR-T potential By Investing.com
Investing.com· 2 days agoThe firm's analysis follows recent presentations at medical conferences that highlighted the...
Why Is Penny Stock Mustang Bio Trading Over 190% On Monday? - Mustang Bio (NASDAQ:MBIO)
Benzinga· 2 days agoMustang was founded by Fortress Biotech Inc FBIO. Monday, the cell therapy-focused company announced...
Fate Therapeutics stock upgraded by Piper Sandler on autoimmune focus By Investing.com
Investing.com· 2 days agoFate Therapeutics is also advancing its Phase I study of ADR-armed FT522 (CD19 CAR-INK) for patients...
